FHTX

Foghorn TherapeuticsA

Nasdaq / Pharmaceuticals, Biotechnology & Life Sciences

At close

2026-07-18

View Chart

AI scenario view

RankAlpha Sentiment Codex

B+

Bull case

20%

Probability

Target price

$9.50

+83.0% vs current

Most likely

Base case

50%

Probability

Target price

$5.60

+7.9% vs current

B-

Bear case

30%

Probability

Target price

$3.20

-38.3% vs current

AI sentiment snapshot

Latest data as of 2026-07-19

AI commentary

Primary company evidence is strong but forward visibility is limited to early clinical progress and anticipated 2027 IND milestones. Secondary post-earnings coverage was negative on revenue and price reaction, while analyst revision and options data are otherwise unavailable. The peer set is market-cap based and loose.

RankAlpha Sentiment Codex - 2026-07-19

Open full AI memo

Evidence flagged

No evidence quality warning is currently attached to this memo.

Impact

standard

Confidence

AI events

2026-10-17eventFHD-909 Phase 1 progress and dose-expansion decisionHigh impact

Foghorn reported that FHD-909 Phase 1 dose escalation and enrollment were on track, with a potential move into dose expansion and combination studies with Lilly pending a decision [#SEC-8K-2026-05-07].

2026-10-17catalystPost-earnings expectation reset remains an overhangHigh impact

A secondary post-earnings summary reported Q1 revenue of $3.3 million, below analyst expectations, a reduction in 2026 revenue consensus to $28.8 million from $33.3 million, and a 5.1% weekly share-price decline; the $11.44 consensus target was unchanged [#PR-EARNINGS-2026-05-11].

2027-07-19catalystFHT-171/CBPd-171 IND milestoneHigh impact

The company reported IND-enabling studies anticipated in 2026 and an IND expected in 2027 for its selective CBP degrader in ER+ breast cancer [#SEC-8K-2026-05-07].

View full catalyst timeline

Recommendation

N/A

No formal recommendation provided.

Open AI Memo

As of 2026-07-19 • Updated nightlySource: Internal modelMethodology